2019 AABB Annual Meeting On-Demand: Cellular Therapy Sessions


Interested in all things Cellular Therapies? Then this is the package for you. We have also thrown in a few additional sessions you might also find interesting. 

The package includes 32 sessions which provide you the opportunity to earn up to 33.75 general credits; 26.75 continuing medical education credits for physicians; 8.75 SAM credits; or, 27.75 California Lab Personnel, Florida Lab Personnel or California Nurse contact hours.

If purchasing these sessions separately it would cost $580/$735 (member/nonmember). Also available is the Cellular Therapies pre-meeting workshop (sold separately).

Members: $199.00
Standard: $249.00

Products

ST1-10: Practical Considerations in Directing an Apheresis Service

Preview Available

ST1-10: Practical Considerations in Directing an Apheresis Service

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Apheresis has been a treatment modality for many conditions. Additionally, it can be used to collect cells for use in hematopoietic progenitor cell transplantations or for further manufacturing into other cellular therapy products for the treatment of malignancy, such as chimeric antigen receptor T cells. The complexity of an apheresis operation is increased dramatically than ever before and thus, the management of this service is often challenging. In this session, key practical considerations to successfully directing an apheresis service will be discussed. Specifically, since having good access is critical to an effective and safe apheresis procedure, different access options for both inpatient and outpatient populations will be discussed and compared. Given many apheresis collection products are considered therapeutic agent and to ensure their efficacy and safety during treatments, they are highly regulated by both the FDA and other accrediting agencies. Therefore, this session will also provide a brief review of basic regulatory standards along with basic principles in equipment validation and management in the field of apheresis. Lastly, medical coding terminology and the reimbursement process in apheresis will be explained to ensure proper and successful billing and communication with third party payers.

Learning Objectives:

  • Review basic of regulations, validation, and quality management in an apheresis service.
  • Discuss and compare several options for access, as well as trouble-shooting for patients undergoing apheresis procedures.
  • Explain medical coding terminology and examine the reimbursement process in apheresis.

Please note: Huy Pham, MD, MPH did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):
  • Jan C. Hofmann, MD, MPH, MSc, Department of Laboratory Medicine, UCSF School of Medicine
  • Lawrence A. Williams, Department of Pathology, University of Alabama at Birmingham; UAB
Standard: $25.00
Members: $20.00

ST1-02: Red Blood Cell Storage: The Oxygen Paradox

Preview Available

ST1-02: Red Blood Cell Storage: The Oxygen Paradox

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Red blood cells are solely responsible for supplying oxygen for mitochondrial metabolism in all the tissues of the body. This critical role has led to the ubiquitous use of red blood cells as a foundation for modern healthcare systems resulting in over 100 million units of blood prescribed globally to improve the oxygen carrying capacity of patients in need. In the body the red cell is uniquely equipped to juggle oxygen and the iron(II) atom in hemoglobin. However, upon storage, physiology is replaced by chemistry. In the presence of an uncontrolled abundance of oxygen the iron(II) is oxidized to iron(III) initiating a cascade of changes during storage that are attributed to oxidative damage which is dependent on the ability of the cell to protect itself from such oxidative damage. Degradation during storage reduces the ability of red blood cells to carry and to deliver oxygen and creates non-red cell by-products that are associated with adverse effects, and do not deliver oxygen; these by-products are transfused along with the red cells. A salient example is the unintended dose of free iron made available to patients under some transfusion conditions that is associated with adverse outcomes such as iron overload and infections.

Learning Objectives:

  • Restate the role oxidative damage plays and the drivers that contribute to changes in red cell physiology during refrigerated storage.
  • Recognize the changes in red cell quality caused by oxidative damage as measured by current techniques.
  • Question the effects of oxidative damage and the role it plays on red cell quality, specifically in assessing successful patient treatment and expected outcomes
  • Identify donor- and process-related red cell characteristics which could mitigate oxidative damage and potential risk to patients.
  • Hypothesize potential opportunities, both short and long term, to improve red cell quality and resulting patient outcomes.

Please note: Angelo D'Alessandro, PhD did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):
Standard: $25.00
Members: $20.00

ST1-08: Developing a Training Program for Future Cellular Therapy Professionals

Preview Available

ST1-08: Developing a Training Program for Future Cellular Therapy Professionals

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

The rapidly growing field of cellular therapy faces a major challenge in the availability of qualified professionals. From technologists to laboratory directors, the current training environment simply has not kept up with the rapid expansion and the novel nature of this exciting new field. Regular medical technologists lack the experience in a current Good Manufacturing Practice (cGMP) environment. Most transfusion medicine trainees have little exposure to the field of cellular therapy, whether it is standard of care, or investigational. There are currently no accredited cellular therapy fellowships by the Accreditation Council for Graduate Medical Education (ACGME). 

This session intend to showcase some of the existing cellular therapy programs, from short to long ones. It aims to bring to the audience's attention currently available, albeit limited, training opportunities in cellular therapy. Furthermore, it also hopes to stimulate attendee's own desire to bring such need back to their own institutions and perhaps design a training program of their own. Only with a pipeline of well trained professionals can this field truly achieve its potential.

Learning Objectives:

  • Appreciate the lack of training opportunities in cellular therapy.
  • Identify currently available training programs in cellular therapy.
  • Design their own training program, depending on the trainees targeted and scope/resources available.

Speaker(s):
Standard: $25.00
Members: $20.00

ST1-09: Bioprinting: Translational Pathway to the Clinic (AABB/TERMIS-AM Joint Session)

Preview Available

ST1-09: Bioprinting: Translational Pathway to the Clinic (AABB/TERMIS-AM Joint Session)

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Bioprinting has become an innovative tool for tissue engineering and regenerative medicine. This technology has been developed to allow construction of biological substitutes mimicking structures and functions of native tissues or organs. 3D Bioprinting enables precise placement of various cell types, biomaterials, and bioactive molecules in a single three-dimensional (3-D) architecture. This session will provide insights into the rapidly developing area of bioprinting and how this technology is being developed for clinical applications as well as the regulatory considerations.

Learning Objectives:

  • Discuss the fundamentals of Biofabrication.
  • Discuss the current status of regulatory oversight.
  • Describe how bioprinting technology is translated into the clinic.

Please note: James Yoo, MD, PhD did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):
Standard: $25.00
Members: $20.00

ST2-11: Ask the Standards

Preview Available

ST2-11: Ask the Standards

Oct 19, 2019 10:00am ‐ Oct 19, 2019 11:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Presentations will be given by standards committee chairs who have new or revised editions to discuss. Questions for the discussion are to be submitted before the scheduled session via the AABB website starting late August, at kiosks in the Cyber Connection located in the Henry B. González Convention Center in San Antonio, and during the session.

At the completion of this session, participants should be able to:

  • Review new and changed standards for newly issued sets of Standards
  • Explain the Standards Creating and Setting Process
  • Explain the difference between Standards and Guidance

Speaker(s):
Standard: $25.00
Members: $20.00

ST2-17: Clinical Applications for Adipose-Tissue Derived Mesenchymal Stem Cells (AABB/IFATS Joint Session)

Preview Available

ST2-17: Clinical Applications for Adipose-Tissue Derived Mesenchymal Stem Cells (AABB/IFATS Joint Session)

Oct 19, 2019 10:00am ‐ Oct 19, 2019 11:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Adipose‐ derived stromal/stem cells (ASC) have shown tremendous promise as therapies for a variety of human diseases, particularly for patients with severe cases refractory to current medical treatments. ASCs possess the capacity for homing, immunomodulation, promotion of repair, and direct regeneration of damaged tissues. The goals for this session will be to (1.) discuss the basic biology and pre-clinical research on ASCs in multiple disease models, and (2.) to present ongoing clinical research on the use of ASCs to treat human diseases. The speakers for this session represent leading experts in the field of ASCs.

Learning Objectives:

  • Discuss the clinical applications of ASCs
  • Discuss the mechanisms by which ASCs combat disease
  • Appreciate the biologic properties of ASCs

Please note: Lauren Kokai did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):
  • Bruce Bunnell, PhD, Tulane University
  • Jaime R Garza, DDS, MD, Professor of Orthopedics and Otolaryngology, Tulane University School of Medicine
Standard: $25.00
Members: $20.00

ST2-19: Emerging Technologies in Continuous Cell Separation for Cellular Therapy and Sickle Cell Disease

Preview Available

ST2-19: Emerging Technologies in Continuous Cell Separation for Cellular Therapy and Sickle Cell Disease

Oct 19, 2019 10:00am ‐ Oct 19, 2019 11:30am
Expiration Date: Dec 31, 2021

Credits: None available.

As life-saving as it is, the basic centrifugal technology behind current apheresis and cell processing devices has remained since their invention. In this session, Dr. Thibodeaux will discuss her team’s method to optimize density centrifugation technology to improve the efficiency of red cell exchange, thus providing a theoretically improved alternative to isovolemic hemodilution to decrease red cell unit usage or increase time intervals between exchanges. Dr. Manis/Fiering will discuss his team’s work using acoustic separation technology to 1) purify lymphocytes and 2) optimize sickle cell gene therapy by selectively enriching for hematopoietic stem cells and improve poor collection efficiency observed with stem cell collections in patients with sickle cell disease owing to the altered centrifugation patterns of sickle red cells. Dr. Chalmers will discuss his team’s work using continuous flow magnetic cell sorting to 1) separate red cells, including sickle from normal donor, based on their intrinsic paramagnetic properties and 2) distinguish relevant cell subsets (such as high-expressing CD34+ cells for gene therapy) by level of antigen expression using magnetically labeled antibodies. 

Learning Objectives:

  • Appraise the science behind developing technologies in continuous cell separation other than density or counterflow centrifugation, such as acoustic and magnetic separation technologies
  • Compare standard density centrifugation methods with newer separation technologies to selectively remove recipient (sickle) and not donor red cells
  • Describe how newer methods can selectively enrich for lymphocytes, hematopoietic stem cells or subsets, and/or enrich or deplete red cell populations.

**This education session will not offer CME. You will be able to claim CE for the session.


Please note: Jason Fiering did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.


Speaker(s):
Standard: $25.00
Members: $20.00

ST3-22: NBF Grant Recipients Lecture and Luncheon

Preview Available

ST3-22: NBF Grant Recipients Lecture and Luncheon

Oct 19, 2019 11:45am ‐ Oct 19, 2019 1:15pm
Expiration Date: Dec 31, 2021

Credits: None available.

This lecture showcases the research activities of three early-career transfusion medicine and cellular therapies investigators who are utilizing or have utilized NBF grant funding to develop their investigations into highly productive transfusion medicine, cellular therapies or patient blood management research programs. The NBF Award for Innovative Research will be awarded at this luncheon to a previous NBF grant recipient who has developed his/her studies into high-profile innovative research with substantial impact that may ultimately lead to improving patient outcomes. Enjoy a delicious lunch while the scientists discuss their latest research with a focus on the role their findings will play in driving the future of transfusion medicine, cellular therapies and patient blood management. Time for questions and informal discussion will be provided. 

This session is supported by an unrestricted educational grant from TerumoBCT.

Please note: Francesca Vinchi, PhD did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):
  • Krystalyn E. Hudson, PhD, Assistant Professor, Department of Pathology and Cell Biology, Columbia University Medical Center
  • Neil Blumberg, MD, Transfusion Medicine, University of Rochester Medical Center
  • Francesca Vinchi, PhD, New York Blood Center
Standard: $20.00
Members: $15.00

ST4-28: Oral Abstract Session: New Concepts in Transfusion-Mediated Immunization and Inflammation

Preview Available

ST4-28: Oral Abstract Session: New Concepts in Transfusion-Mediated Immunization and Inflammation

Oct 19, 2019 1:30pm ‐ Oct 19, 2019 3:00pm
Expiration Date: Dec 31, 2021

Credits: None available.

Oral Abstract Session

6718: Mechanisms of Antibody-Mediated RBC Removal: Consequences on Prevention and Treatment
Presenting Author: Dr. Satheesh Chonat

6460: Antigen Density and Concentration of RBC-Specific Alloantibodies Alters Biology of Incompatible Transfusion
Presenting Author: Dr. Krystalyn E. Hudson

6344: Redirecting Inflammation with an Anti-Erythrocyte Antibody
Presenting Author: Dr. Alan Lazarus

6767: Antibodies to One RBC Antigen Can Boost Immunity to a Completely Distinct Antigen
Presenting Author: Cheryl L. Maier

6279: Comparison of Different Induction Factor Expanded CD8 Regulatory T Cells in Vitro
Presenting Author: Ms. Juan Sun

Please note: Juan Sun did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):
  • Satheesh Chonat, M.D, Emory University School of Medicine; Aflac CAncer and Blood Disorders Center
  • Krystalyn E. Hudson, PhD, Assistant Professor, Department of Pathology and Cell Biology, Columbia University Medical Center
  • Alan Lazarus, PhD, The Canadian Blood Services Centre for Innovation
  • Cheryl L Maier, MD, PhD, Emory School of Medicine
  • Juan Sun, Shanghai Blood Center
Standard: $25.00
Members: $20.00

ST4-32: Bringing Animal Models, Human Studies and Epidemiology Together to Understand RBC Alloimmunization

Preview Available

ST4-32: Bringing Animal Models, Human Studies and Epidemiology Together to Understand RBC Alloimmunization

Oct 19, 2019 1:30pm ‐ Oct 19, 2019 3:00pm
Expiration Date: Dec 31, 2021

Credits: None available.

While red blood cell (RBC) transfusion represents one of the most common interventions in hospitalized patients, transfusion is not without risk. Allogeneic RBC exposure can result in the development of RBC alloantibodies, which can delay subsequent transfusions and lead to life-threatening complications. Recent data generated using animal models, sophisticated human immunology and epidemiological studies have resulted in an unprecedented growth in the field of RBC alloimmunization. This session will integrate findings obtained in a variety of animal models, human immunology and a growing number of epidemiological studies that have all been designed to understand factors that regulate RBC alloimmunization. In doing so, this session will assimilate these different fields to provide a greater understanding of the factors that may predict and ultimately prevent RBC alloimmunization in at risk patients.

Learning Objectives:

  • Define distinct differences in RBC alloimmunization immune pathways as defined by recent animal models of alloimmunization.
  • Discuss the unique immune responses that correlate with alloantibody responder status in chronically transfused patients with sickle cell disease.
  • Identify key epidemiological associations in transfused recipients that correlate with the likelihood of developing alloantibodies following RBC transfusion.

Please note: Karina Yazdanbakhsh, PhD and Jaap Jan Zwaginga did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):
Standard: $20.00
Members: $15.00
Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content